JP2020524710A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524710A5
JP2020524710A5 JP2020520192A JP2020520192A JP2020524710A5 JP 2020524710 A5 JP2020524710 A5 JP 2020524710A5 JP 2020520192 A JP2020520192 A JP 2020520192A JP 2020520192 A JP2020520192 A JP 2020520192A JP 2020524710 A5 JP2020524710 A5 JP 2020524710A5
Authority
JP
Japan
Prior art keywords
antigen
vlp
protein
peptide
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524710A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038701 external-priority patent/WO2018237115A2/en
Publication of JP2020524710A publication Critical patent/JP2020524710A/ja
Publication of JP2020524710A5 publication Critical patent/JP2020524710A5/ja
Pending legal-status Critical Current

Links

JP2020520192A 2017-06-23 2018-06-21 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用 Pending JP2020524710A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762524308P 2017-06-23 2017-06-23
US62/524,308 2017-06-23
US201862676566P 2018-05-25 2018-05-25
US62/676,566 2018-05-25
PCT/US2018/038701 WO2018237115A2 (en) 2017-06-23 2018-06-21 Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses

Publications (2)

Publication Number Publication Date
JP2020524710A JP2020524710A (ja) 2020-08-20
JP2020524710A5 true JP2020524710A5 (https=) 2021-07-29

Family

ID=64737338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520192A Pending JP2020524710A (ja) 2017-06-23 2018-06-21 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用

Country Status (13)

Country Link
US (3) US11285203B2 (https=)
EP (1) EP3641809A4 (https=)
JP (1) JP2020524710A (https=)
KR (1) KR102797824B1 (https=)
CN (1) CN110891602A (https=)
AU (1) AU2018289540B2 (https=)
BR (1) BR112019027488A2 (https=)
CA (1) CA3068012A1 (https=)
IL (1) IL271461B2 (https=)
MX (1) MX2019015769A (https=)
MY (1) MY202196A (https=)
SG (1) SG11201912480SA (https=)
WO (1) WO2018237115A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813329B2 (en) * 2014-10-24 2023-11-14 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine
KR102797824B1 (ko) * 2017-06-23 2025-04-17 버이뮨 아이엔씨. 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
SG11202106931PA (en) * 2018-12-27 2021-07-29 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
IL302190A (en) * 2020-10-19 2023-06-01 Verimmune Inc Virus-induced preparations and methods for redirecting immune responses in the use of said preparations for cancer treatment
CN115960262A (zh) * 2022-10-19 2023-04-14 四川农业大学 展示cdv抗原表位的犬细小病毒样颗粒及构建方法和应用
TW202502376A (zh) * 2023-06-06 2025-01-16 美商弗免疫股份有限公司 包含病毒樣蛋白及檢查點抑制劑之病毒啟發組合物及使用其治療癌症之方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
EA004497B1 (ru) 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
SE514982C2 (sv) 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
AU2004238843B2 (en) 2003-05-09 2009-04-23 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
KR20080015854A (ko) * 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 항원 컨쥬게이트 및 그의 용도
US20070160628A1 (en) 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JP5564181B2 (ja) 2005-12-08 2014-07-30 シルワン,ハヴァル 免疫刺激組成物および方法
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
HUE030437T2 (en) 2007-05-08 2017-05-29 Us Health Papillomavirus pseudoviruses for detection and therapy of tumors
US8088392B2 (en) 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
WO2009092113A2 (en) 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
EP2288380B1 (en) 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010118424A2 (en) 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2012033911A2 (en) * 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
CN102153656B (zh) * 2011-01-12 2014-11-19 广州市元通医药科技有限公司 一种嵌合病毒样颗粒疫苗及其制备方法
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
SG11201401579UA (en) 2011-12-01 2014-07-30 Univ Cape Town Hpv chimaeric particle
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US9561275B2 (en) 2012-09-14 2017-02-07 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing
US20160206715A1 (en) 2013-03-15 2016-07-21 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
MX385842B (es) 2013-09-18 2025-03-18 Aura Biosciences Inc Conjugados de partículas de tipo virus y uso de las mismas.
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
US10413603B2 (en) 2014-06-19 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for improved human papilloma virus constructs
WO2016112921A1 (en) * 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
EP3258969B1 (en) 2015-02-18 2019-03-20 F. Hoffmann-La Roche AG Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
WO2016176164A1 (en) 2015-04-28 2016-11-03 Albert Einstein College Of Medicine, Inc. Treatment of cancer using recall antigens delivered by attenuated bacteria
WO2017020570A1 (en) 2015-08-06 2017-02-09 Medigen Biotechnology Corp. Virus-like particle vaccines
WO2017075615A1 (en) * 2015-10-29 2017-05-04 Bullet Biotechnology, Inc. Virus-like particle intermediates, agents attached thereto, methods for making and uses thereof
WO2017075440A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
US20180311374A1 (en) 2015-10-30 2018-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Targeted cancer therapy
ES2854726T3 (es) 2015-10-30 2021-09-22 The Univ Of Copenhagen Partícula similar a virus con presentación eficiente de epítopos
US10722537B2 (en) 2015-11-06 2020-07-28 Regents Of The University Of Minnesota Activation of resident memory T cells for cancer immunotherapy
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017112830A1 (en) 2015-12-21 2017-06-29 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
US11351237B2 (en) 2015-12-22 2022-06-07 Thomas Jefferson University CMV-based intra-tumoral cancer therapies
GB201603625D0 (en) * 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
US20200078401A1 (en) 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US11197890B2 (en) 2016-12-12 2021-12-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
KR102797824B1 (ko) * 2017-06-23 2025-04-17 버이뮨 아이엔씨. 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
EP3661550A4 (en) 2017-08-03 2021-08-04 Regents of the University of Minnesota ACTIVATION OF LYMPHOCYTES T MEMORY RESIDENTS FOR THE TREATMENT OF CANCER
EP3706783A1 (en) 2017-11-06 2020-09-16 The United States of America, as represented by the Secretary, Department of Health and Human Services Cancer treatment utilizing pre-existing microbial immunity
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
DE102018123327A1 (de) * 2018-09-21 2020-03-26 Christian Uhlik Modulares Raumluft-Behandlungssystem
SG11202106931PA (en) * 2018-12-27 2021-07-29 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
KR20210151848A (ko) 2019-03-26 2021-12-14 아우라 바이오사시언시스, 인크. 인간 파필로마바이러스 나노입자 제제
IL302190A (en) * 2020-10-19 2023-06-01 Verimmune Inc Virus-induced preparations and methods for redirecting immune responses in the use of said preparations for cancer treatment

Similar Documents

Publication Publication Date Title
JP2020524710A5 (https=)
US12528839B2 (en) Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
AU750702B2 (en) Use of virus-like particles as adjuvants
CN108434450B (zh) 基于铁蛋白纳米颗粒的疫苗及其制备方法
Zhang et al. Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances
Garcea et al. Virus-like particles as vaccines and vessels for the delivery of small molecules
JP2005507388A5 (https=)
MXPA05009289A (es) Conjugados de particulas tipo virus del analogo del peptido melan-a.
CN103347892B (zh) 单体和多聚体免疫原性肽
JP2007504237A5 (https=)
JP2006514920A5 (https=)
KR102797824B1 (ko) 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
JP2012501347A5 (https=)
Gao et al. Nanovaccines for advancing long-lasting immunity against infectious diseases
WO2005060993A1 (en) Synthetic protein as tumor-specific vaccine
Peacey et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
JPWO2020139978A5 (https=)
CN116157149A (zh) 改造的牛分枝杆菌疫苗
JP2003514576A5 (https=)
Pa et al. Protein nanocages: A new frontier in mucosal vaccine delivery and immune activation
Wang et al. Current status and future trends of vaccine development against viral infection and disease
Yang et al. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response
WO2006024240A2 (es) Composición vacunal contra el virus de la hepatitis c.
El Battioui et al. Progress in the development of vaccines against human papillomavirus
Im et al. Prevention of cervical cancer with vaccines